风险提示：股市有风险，投资需谨慎。 金凯生科是一家面向全球生命科技领域的小分子CDMO服务商，专注于为原研药厂提供新药研发过程中 的定制研发生产服务，涵盖工艺开发、优化及规模化生产等环节。公司所属板块包括生物制品、 CRO、减肥药等。 8月23日披露的半年报显示，公司上半年实现营收3.48亿元，同比增长32.98%；归母净利润7176.06万 元，同比增长123.61%；扣非净利润5917.48万元，同比增长141.51%。经营活动现金流净额7471.88万 元，同比增长14.47%。 今日主力资金净流出1971.50万元，占流通市值的0.81%；近五日主力资金累计净流出70.95万元，占流 通市值的0.03%。 金凯生科股价报42.65元，较前一交易日下跌1.15元，跌幅2.63%。盘中最高触及44.19元，最低下探至 42.58元，成交额3.01亿元，换手率12.27%。 ...

Core Viewpoint - The company Jin Kai Sheng Ke (301509) is currently focused on small molecule CDMO services in the life sciences sector and does not engage in the PEEK materials field [1] Group 1 - The company is concentrating its efforts on the life sciences domain [1] - The existing products and services of the company do not involve PEEK materials [1]

Group 1 - The company, Jinkai Biotechnology (301509), positions itself as a global small molecule CDMO service provider in the life sciences sector [1] - The main services offered by the company include process development, process optimization, process scale-up, and large-scale production for clients in the innovative drug development process [1]